Check-cap announces receipt of nasdaq minimum bid price notification

Isfiya, israel, dec. 23, 2021 /prnewswire/ -- check-cap ltd. (the "company" or "check-cap") (nasdaq: chek), (nasdaq: chekz), a clinical stage medical diagnostics company advancing the development of c-scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (crc), today announced that the company received a letter from the nasdaq listing qualifications (the "letter"), indicating that the company is not in compliance with the minimum bid price requirement for continued listing set forth in listing rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
CHEK Ratings Summary
CHEK Quant Ranking